Seikagaku and its subsidiaries are mainly engaged in the research and development, manufacture, purchase and sale of medical devices specifically related to glycoconjugates. Co. operates in two business segments. Pharmaceutical segment offers pharmaceutical products made from hyaluronic acid, a major component of glycoconjugates including joint function improving agents, ophthalmic surgical aids, surgical aids for endoscopic mucosal resection, and bulk products. Limulus amebocyte lysate ("LAL") segment offers endotoxin-detecting reagents made from LAL and other, to be used for quality control in the manufacturing process of pharmaceuticals and release test and medical devices.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.